PPARs, RXRs, and Stem CellsView this Special Issue
Research Article | Open Access
Daniel Rivas, Rahima Akter, Gustavo Duque, "Inhibition of Protein Farnesylation Arrests Adipogenesis and Affects PPAR Expression and Activation in Differentiating Mesenchymal Stem Cells", PPAR Research, vol. 2007, Article ID 081654, 7 pages, 2007. https://doi.org/10.1155/2007/81654
Inhibition of Protein Farnesylation Arrests Adipogenesis and Affects PPAR Expression and Activation in Differentiating Mesenchymal Stem Cells
Protein farnesylation is required for the activation of multiple proteins involved in cell differentiation and function. In white adipose tissue protein, farnesylation has shown to be essential for the successful differentiation of preadipocytes into adipocytes. We hypothesize that protein farnesylation is required for PPAR2 expression and activation, and therefore for the differentiation of human mesenchymal stem cells (MSCs) into adipocytes. MSCs were plated and induced to differentiate into adipocytes for three weeks. Differentiating cells were treated with either an inhibitor of farnesylation (FTI-277) or vehicle alone. The effect of inhibition of farnesylation in differentiating adipocytes was determined by oil red O staining. Cell survival was quantified using MTS Formazan. Additionally, nuclear extracts were obtained and prelamin A, chaperon protein HDJ-2, PPAR, and SREBP-1 were determined by western blot. Finally, DNA binding PPAR activity was determined using an ELISA-based PPAR activation quantification method. Treatment with an inhibitor of farnesylation (FTI-277) arrests adipogenesis without affecting cell survival. This effect was concomitant with lower levels of PPAR expression and activity. Finally, accumulation of prelamin A induced an increased proportion of mature SREBP-1 which is known to affect PPAR activity. In summary, inhibition of protein farnesylation arrests the adipogenic differentiation of MSCs and affects PPAR expression and activity.
- D. Goltzman, “Discoveries, drugs and skeletal disorders,” Nature Reviews Drug Discovery, vol. 1, no. 10, pp. 784–796, 2002.
- L. G. Raisz and E. Seeman, “Causes of age-related bone loss and bone fragility: an alternative view,” Journal of Bone and Mineral Research, vol. 16, no. 11, pp. 1948–1952, 2001.
- G. Duque and B. Troen, “Osteoporosis,” in Hazzard's Textbook in Geriatric Medicine, W. R. Hazzard et al., Ed., McGraw-Hill, New York, NY, USA, 6 edition, 2007, chapter 75.
- G. K. Chan and G. Duque, “Age-related bone loss: old bone, new facts,” Gerontology, vol. 48, no. 2, pp. 62–71, 2002.
- B. Lecka-Czernik, E. J. Moerman, D. F. Grant, J. M. Lehmann, S. C. Manolagas, and R. L. Jilka, “Divergent effects of selective peroxisome proliferator-activated receptor-2 ligands on adipocyte versus osteoblast differentiation,” Endocrinology, vol. 143, no. 6, pp. 2376–2384, 2002.
- J. L. Kirkland, T. Tchkonia, T. Pirtskhalava, J. Han, and I. Karagiannides, “Adipogenesis and aging: does aging make fat go MAD?” Experimental Gerontology, vol. 37, no. 6, pp. 757–767, 2002.
- J. L. Kirkland and D. E. Dobson, “Preadipocyte function and aging: links between age-related changes in cell dynamics and altered fat tissue function,” Journal of the American Geriatrics Society, vol. 45, no. 8, pp. 959–967, 1997.
- L. Pei and P. Tontonoz, “Fat's loss is bone's gain,” Journal of Clinical Investigation, vol. 113, no. 6, pp. 805–806, 2004.
- T. Akune, S. Ohba, S. Kamekura et al., “PPARinsufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004.
- T. Tchkonia, Y. D. Tchoukalova, N. Giorgadze et al., “Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots,” American Journal of Physiology. Endocrinology and Metabolism, vol. 288, no. 1, pp. E267–E277, 2005.
- D. J. Klemm, J. W. Leitner, P. Watson et al., “Insulin-induced adipocyte differentiation: activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation,” Journal of Biological Chemistry, vol. 276, no. 30, pp. 28430–28435, 2001.
- R. D. Moir and T. P. Spann, “The structure and function of nuclear lamins: implications for disease,” Cellular and Molecular Life Sciences, vol. 58, no. 12-13, pp. 1748–1757, 2001.
- R. L. Boguslavsky, C. L. Stewart, and H. J. Worman, “Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy,” Human Molecular Genetics, vol. 15, no. 4, pp. 653–663, 2006.
- T. Sullivan, D. Escalante-Alcalde, H. Bhatt et al., “Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy,” Journal of Cell Biology, vol. 147, no. 5, pp. 913–920, 1999.
- C. Capanni, E. Mattioli, M. Columbaro et al., “Altered pre-lamin a processing is a common mechanism leading to lipodystrophy,” Human Molecular Genetics, vol. 14, no. 11, pp. 1489–1502, 2005.
- G. Duque and D. Rivas, “Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells,” Journal of Bone and Mineral Research, vol. 22, no. 10, pp. 1603–1611, 2007.
- B. C. Capell, M. R. Erdos, J. P. Madigan et al., “Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 36, pp. 12879–12884, 2005.
- G. Duque, K. E. Abdaimi, M. Macoritto, M. M. Miller, and R. Kremer, “Estrogens regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation,” Biochemical and Biophysical Research Communications, vol. 299, no. 3, pp. 446–454, 2002.
- G. Duque, M. Macoritto, and R. Kremer, “Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity,” Biogerontology, vol. 5, no. 6, pp. 421–429, 2004.
- M. E. Nuttall and J. M. Gimble, “Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?” Bone, vol. 27, no. 2, pp. 177–184, 2000.
- J. E. Aubin and J. T. Triffitt, “Mesenchymal stem cells and osteoblast differentiation,” in Principles of Bone Biology, pp. 59–81, Academic Press, Boston, Mass, USA, 2nd edition, 2002.
- S.-C. Hung, C.-F. Chang, H.-L. Ma, T.-H. Chen, and L. Low-Tone Ho, “Gene expression profiles of early adipogenesis in human mesenchymal stem cells,” Gene, vol. 340, no. 1, pp. 141–150, 2004.
- G. Duque, M. Macoritto, and R. Kremer, “ inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2 (PPAR2),” Experimental Gerontology, vol. 39, no. 3, pp. 333–338, 2004.
- A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka, “Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation,” Endocrinology, vol. 146, no. 3, pp. 1226–1235, 2005.
- S. G. Young, L. G. Fong, and S. Michaelis, “Prelamin A, Zmpste24, misshapen cell nuclei, and progeria-new evidence suggesting that protein farnesylation could be important for disease pathogenesis,” Journal of Lipid Research, vol. 46, no. 12, pp. 2531–2558, 2005.
- Y. Liu, A. Rusinol, M. Sinensky, Y. Wang, and Y. Zou, “DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A,” Journal of Cell Science, vol. 119, no. 22, pp. 4644–4649, 2006.
- C. J. Lelliott, L. Logie, C. P. Sewter et al., “Lamin expression in human adipose cells in relation to anatomical site and differentiation state,” Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 2, pp. 728–734, 2002.
- J. P. DeLany, Z. E. Floyd, S. Zvonic et al., “Proteomic analysis of primary cultures of human adipose-derived stem cells,” Molecular & Cellular Proteomics, vol. 4, no. 6, pp. 731–740, 2005.
- A. A. Adjei, J. N. Davis, C. Erlichman, P. A. Svingen, and S. H. Kaufmann, “Comparison of potential markers of farnesyltransferase inhibition,” Clinical Cancer Research, vol. 6, no. 6, pp. 2318–2325, 2000.
- M. Caron, M. Auclair, H. Sterlingot, M. Kornprobst, and J. Capeau, “Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation,” AIDS, vol. 17, no. 17, pp. 2437–2444, 2003.
Copyright © 2007 Daniel Rivas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.